Advanced Search

Technical Analysis for GRCL - Gracell Biotechnologies Inc.

Grade Last Price % Change Price Change
F 14.65 5.47% 0.76
GRCL closed up 2.89 percent on Monday, April 12, 2021, on 50 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Up
Historical GRCL trend table...
Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 5.47%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 5.47%
Narrow Range Bar Range Contraction 5.47%
NR7 Range Contraction 5.47%
Inside Day Range Contraction 5.47%
Wide Bands Range Expansion 5.47%
Oversold Stochastic Weakness 5.47%
1,2,3 Retracement Bearish Bearish Swing Setup 8.52%
180 Bearish Setup Bearish Swing Setup 8.52%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 8.52%
Older End-of-Day Signals for GRCL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 5% about 3 hours ago
Rose Above Previous Day's High about 4 hours ago
Outside Day about 4 hours ago
Up 3% about 4 hours ago
Up 2% about 4 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators Basic chart:

Profile

  • Earnings date: ???
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Solid Tumors Immune System Health Sciences Lymphoma Cancer Immunotherapy Gene Therapy Chimeric Antigen Receptor T Cell

Is GRCL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Apr 10 Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the AACR 2021 Annual Meeting
Apr 8 What Type Of Shareholders Make Up Gracell Biotechnologies Inc.'s (NASDAQ:GRCL) Share Registry?
Apr 5 Gracell Biotechnologies to Present at the 20th Annual Needham Virtual Healthcare Conference
Mar 31 Gracell partners with Lonza to manufacture CAR-T cell candidates in U.S.
Mar 31 Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S.
Mar 31 Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL
Mar 26 The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs
Mar 17 Gracell Biotechnologies to Participate in the 2021 Virtual Wells Fargo Biotech Corporate Access Day
Mar 10 Gracell Biotechnologies, Inc. (GRCL) CEO Dr. William Cao on Q4 2020 Results - Earnings Call Transcript
Mar 10 Gracell Biotechnologies Inc - ADR to Host Earnings Call
See more GRCL news...

Indicators

Indicator Value
52 Week High 33.6999
52 Week Low 12.3
Average Volume 104,491
200-Day Moving Average 0.00
50-Day Moving Average 22.35
20-Day Moving Average 18.00
10-Day Moving Average 14.01
Average True Range 1.87
ADX 31.0
+DI 15.51
-DI 27.24
Chandelier Exit (Long, 3 ATRs ) 19.08
Chandelier Exit (Short, 3 ATRs ) 17.90
Upper Bollinger Band 26.67
Lower Bollinger Band 9.34
Percent B (%b) 0.26
BandWidth 96.23
MACD Line -2.66
MACD Signal Line -2.38
MACD Histogram -0.2776
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.26
Resistance 3 (R3) 15.26 14.82 15.03
Resistance 2 (R2) 14.82 14.47 14.81 14.95
Resistance 1 (R1) 14.35 14.25 14.13 14.35 14.88
Pivot Point 13.91 13.91 13.80 13.90 13.91
Support 1 (S1) 13.44 13.56 13.22 13.44 12.90
Support 2 (S2) 13.00 13.34 12.99 12.83
Support 3 (S3) 12.53 13.00 12.75
Support 4 (S4) 12.53